Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 24, 2023
Discovery & Translation
Link’s AND-gated CAR T cells, plus a rapid COVID test with PCR-like sensitivity and more
BioCentury’s roundup of translational news
BioCentury | Dec 7, 2022
Distillery Therapeutics
A spike- and nucleoprotein-targeting mRNA vaccine for SARS-CoV-2
BioCentury | Jul 30, 2021
Distillery Therapeutics
Disruption of SARS-CoV-2 nucleocapsid-mediated immune evasion to treat COVID-19
DISEASE CATEGORY: Infectious disease
INDICATION: Coronavirus disease (COVID-19) A peptide that targets the SARS-CoV-2 N dimerization domain could treat COVID-19 by relieving suppression of
INDICATION: Coronavirus disease (COVID-19) A peptide that targets the SARS-CoV-2 N dimerization domain could treat COVID-19 by relieving suppression of
BioCentury | Jul 29, 2021
Distillery Therapeutics
Long-chain polyphosphates for COVID-19 prophylaxis and treatment
DISEASE CATEGORY: Infectious disease
INDICATION: Coronavirus disease (COVID-19) A team of South Korean and Italian researchers showed long-chain polyphosphates could treat and prevent COVID-19. In
INDICATION: Coronavirus disease (COVID-19) A team of South Korean and Italian researchers showed long-chain polyphosphates could treat and prevent COVID-19. In
BioCentury | Feb 23, 2021
Distillery Therapeutics
CRISPR-Cas13a targeting of viral genes for COVID-19, flu
DISEASE CATEGORY: Infectious disease
INDICATION: Coronavirus; influenza CRISPR-Cas13a knockdown of the nucleocapsid protein of SARS-CoV-2 or influenza’s viral RNA polymerase could
INDICATION: Coronavirus; influenza CRISPR-Cas13a knockdown of the nucleocapsid protein of SARS-CoV-2 or influenza’s viral RNA polymerase could
BioCentury | Feb 4, 2021
Product Development
Vaxart falls on mixed Phase I readout for COVID-19 vaccine; plus BMS-Rockefeller mAb cocktail deal and vaccine updates for Sputnik V, Novavax, Bharat-Ocugen and Sinovac
Vaxart Inc. (NASDAQ:VXRT) lost $13.81 (59%) to $9.52 Wednesday on preliminary Phase I data for VXA-CoV2-1. The data showed the vaccine did evoke CD8+ T cell and IgA responses but no detectable serum
BioCentury | Nov 13, 2020
Translation in Brief
Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more
BioCentury’s roundup of translational news
BioCentury | Sep 2, 2020
Product Development
COVID-19 Quick Takes: NAS framework on vaccine allocation prioritizes higher risk groups
Plus Soriot reiterates AZ’s commitment to ‘follow the science,’ deliver equitable access
Items per page:
1 - 10 of 18